<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01868243</url>
  </required_header>
  <id_info>
    <org_study_id>DAWA2013</org_study_id>
    <nct_id>NCT01868243</nct_id>
  </id_info>
  <brief_title>Dabigatran Versus Warfarin After Mitral and/or Aortic Bioprosthesis Replacement and Atrial Fibrillation Postoperatively</brief_title>
  <acronym>DAWA</acronym>
  <official_title>Dabigatran Versus Warfarin After Mitral and Aortic Bioprosthesis Replacement for the Management of Atrial Fibrillation Postoperatively: Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Ana Nery</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Ana Nery</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      DAWA is a phase 2, prospective, open-label, randomized, pilot study. The main variable to be
      observed in this study is intracardiac thrombus. There are no formal primary or secondary
      clinical efﬁcacy or safety outcomes because it is a pilot study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Mortality and morbidity events (reversible ischemic neurological deficit, ischemic and
      hemorrhagic stroke, systemic embolism, any bleeding, prosthesis valve thrombosis and death)
      were evaluated in an exploratory manner. The details of the trial design have been previously
      described.8 The trial protocol was approved by the local ethics and research committee in the
      city of Salvador-Brazil, and written informed consent was obtained from all patients. An
      independent data and safety monitoring board closely monitored the trial. All the members
      contributed to the interpretation of the results, wrote the first version of the manuscript
      and approved all versions, made the decision to submit the manuscript for publication, and
      vouch for the accuracy and completeness of the data reported and the fidelity of this article
      to the study protocol.

      Patients eligible for inclusion in the study were 18 to 64 years old, underwent mitral and/or
      aortic bioprosthesis valve replacement at least 3 months prior to entering the study and had
      documented AF postoperatively in addition to exclusion of atrial thrombus or valve prosthesis
      thrombosis by transesophageal echocardiography (TEE). Non-contrast brain computed tomography
      (CT) without hemorrhage or findings of acute cerebral infarction on the last 2 days of
      screening was also necessary.

      Patients were randomly assigned to receive dabigatran or warfarin by a computer generated
      list of random numbers performed to 1:1 ratio between the groups. Following that, the
      allocation sequence was concealed from the researcher enrolling participants in sequentially
      numbered, opaque, black, sealed envelopes. After randomization, patients had study visits
      scheduled at 7 days (via telephone) and at 30 days (personally) with a monthly follow-up for
      90 days. After this, non-contrast brain CT and TEE were repeated. The former was executed to
      document possible cerebral events with no clinical expression and the latter to analyze the
      incidence of intracardiac thrombi, new dense spontaneous echo contrast (SEC) or its
      resolution, in addition to thrombosis or dysfunction of valvular prosthesis.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    because a significant decrease of viable candidates for the study.
  </why_stopped>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intracardiac Thrombus</measure>
    <time_frame>90 days</time_frame>
    <description>The primary endpoint was the detection of intracardiac thrombus in TEE at the end of follow-up (90 days).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Spontaneous Echo Contrast</measure>
    <time_frame>90 days</time_frame>
    <description>Spontaneous Echo Contrast showed in Transesophageal echocardiography</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Primary Disease</condition>
  <arm_group>
    <arm_group_label>Dabigatran</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dabigatran 110 mg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Warfarin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Warfarin adjusted-dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran</intervention_name>
    <description>Group 1 - Dabigatran 110 mg (50 patients)</description>
    <arm_group_label>Dabigatran</arm_group_label>
    <other_name>Pradaxa® (dabigatran etexilate) 110mg twice daily</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin</intervention_name>
    <description>Warfarin adjusted-dose</description>
    <arm_group_label>Warfarin</arm_group_label>
    <other_name>Warfarin adjusted-dose</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age from 18 to 64 years at entry

          2. Patients with mitral and/or aorthic valve bioprosthesis for at least 3 months
             postoperatively

          3. There is 12-lead electrocardiogram documented AF on the day of screening or
             randomization; or a 24-hour Holter electrocardiogram recording showing AF episodes
             postoperatively

          4. Brain computed tomography scan without hemorrhage or findings of acute cerebral
             infarction on the last 2 days of screening

          5. Exclusion of atrial thrombus or valve prosthesis thrombosis by transesophageal
             echocardiograph on the last 2 days of screening

          6. Written, informed consent

        Exclusion Criteria:

          1. Previous hemorrhagic stroke

          2. Ischemic stroke in the last 6 months

          3. Severe renal impairment (creatinine clearance rates &lt; 30 ml/min)

          4. Active liver disease (any etiology)

          5. Concomitant use of any antiplatelet (aspirin, clopidogrel, prasugrel, ticagrelor,
             ticlopidine, etc)

          6. Increased risk of bleeding (congenital or acquired)

          7. Uncontrolled hypertension

          8. Gastrointestinal hemorrhage within the past year

          9. Anemia (hemoglobin level &lt;10 g/dL) or thrombocytopenia (platelet count &lt; 100 × 109/L)

         10. Active infective endocarditis

         11. Pregnant or lactating women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andre R Duraes, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Ana Nery</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Ana Nery</name>
      <address>
        <city>Salvador</city>
        <state>Bahia</state>
        <zip>40320010</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez-Sarano M. Burden of valvular heart diseases: a population-based study. Lancet. 2006 Sep 16;368(9540):1005-11.</citation>
    <PMID>16980116</PMID>
  </reference>
  <reference>
    <citation>Carapetis JR, Steer AC, Mulholland EK, Weber M. The global burden of group A streptococcal diseases. Lancet Infect Dis. 2005 Nov;5(11):685-94. Review.</citation>
    <PMID>16253886</PMID>
  </reference>
  <reference>
    <citation>Sun JC, Davidson MJ, Lamy A, Eikelboom JW. Antithrombotic management of patients with prosthetic heart valves: current evidence and future trends. Lancet. 2009 Aug 15;374(9689):565-76. doi: 10.1016/S0140-6736(09)60780-7. Review.</citation>
    <PMID>19683642</PMID>
  </reference>
  <reference>
    <citation>Heras M, Chesebro JH, Fuster V, Penny WJ, Grill DE, Bailey KR, Danielson GK, Orszulak TA, Pluth JR, Puga FJ, et al. High risk of thromboemboli early after bioprosthetic cardiac valve replacement. J Am Coll Cardiol. 1995 Apr;25(5):1111-9.</citation>
    <PMID>7897124</PMID>
  </reference>
  <reference>
    <citation>Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009 Sep 17;361(12):1139-51. doi: 10.1056/NEJMoa0905561. Epub 2009 Aug 30. Erratum in: N Engl J Med. 2010 Nov 4;363(19):1877.</citation>
    <PMID>19717844</PMID>
  </reference>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 28, 2013</study_first_submitted>
  <study_first_submitted_qc>June 3, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2013</study_first_posted>
  <results_first_submitted>June 24, 2015</results_first_submitted>
  <results_first_submitted_qc>September 14, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 9, 2015</results_first_posted>
  <last_update_submitted>September 14, 2015</last_update_submitted>
  <last_update_submitted_qc>September 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Ana Nery</investigator_affiliation>
    <investigator_full_name>Andre Duraes, PhD</investigator_full_name>
    <investigator_title>Andre Rodrigues Duraes</investigator_title>
  </responsible_party>
  <keyword>Atrial Fibrillation</keyword>
  <keyword>Bioprosthesis</keyword>
  <keyword>Stroke</keyword>
  <keyword>Dabigatran</keyword>
  <keyword>Warfarin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warfarin</mesh_term>
    <mesh_term>Dabigatran</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Dabigatran</title>
          <description>Dabigatran 110 mg BID
Dabigatran: Group 1 - Dabigatran 110 mg</description>
        </group>
        <group group_id="P2">
          <title>Warfarin</title>
          <description>Warfarin adjusted-dose
Warfarin: Warfarin adjusted-dose (INR 2.0-3.0)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dabigatran</title>
          <description>Dabigatran 110 mg BID
Dabigatran: Group 1 - Dabigatran 110 mg (50 patients)</description>
        </group>
        <group group_id="B2">
          <title>Warfarin</title>
          <description>Warfarin adjusted-dose
Warfarin: Warfarin adjusted-dose</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="27"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49" spread="10"/>
                    <measurement group_id="B2" value="46" spread="6"/>
                    <measurement group_id="B3" value="47" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Brazil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Intracardiac Thrombus</title>
        <description>The primary endpoint was the detection of intracardiac thrombus in TEE at the end of follow-up (90 days).</description>
        <time_frame>90 days</time_frame>
        <population>A total of 34 patients were selected between August 2013 and November 2014 (6 were excluded for previous intracardiac thrombus; 1 for unstable INR control). Of the 27 randomized, 15 were assigned to receive dabigatran and 12 to receive warfarin.</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran</title>
            <description>Dabigatran 110 mg BID
Dabigatran: Group 1 - Dabigatran 110 mg</description>
          </group>
          <group group_id="O2">
            <title>Warfarin</title>
            <description>Warfarin adjusted-dose
Warfarin: Warfarin adjusted-dose (INR 2.0-3.0)</description>
          </group>
        </group_list>
        <measure>
          <title>Intracardiac Thrombus</title>
          <description>The primary endpoint was the detection of intracardiac thrombus in TEE at the end of follow-up (90 days).</description>
          <population>A total of 34 patients were selected between August 2013 and November 2014 (6 were excluded for previous intracardiac thrombus; 1 for unstable INR control). Of the 27 randomized, 15 were assigned to receive dabigatran and 12 to receive warfarin.</population>
          <units>participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="1" lower_limit="0.9" upper_limit="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Spontaneous Echo Contrast</title>
        <description>Spontaneous Echo Contrast showed in Transesophageal echocardiography</description>
        <time_frame>90 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran</title>
            <description>Dabigatran 110 mg BID
Dabigatran: Group 1 - Dabigatran 110 mg</description>
          </group>
          <group group_id="O2">
            <title>Warfarin</title>
            <description>Warfarin adjusted-dose
Warfarin: Warfarin adjusted-dose (INR 2.0-3.0)</description>
          </group>
        </group_list>
        <measure>
          <title>Spontaneous Echo Contrast</title>
          <description>Spontaneous Echo Contrast showed in Transesophageal echocardiography</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Dabigatran</title>
          <description>Dabigatran 110 mg BID
Dabigatran: Group 1 - Dabigatran 110 mg</description>
        </group>
        <group group_id="E2">
          <title>Warfarin</title>
          <description>Warfarin adjusted-dose
Warfarin: Warfarin adjusted-dose (INR 2.0-3.0)</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Stroke</sub_title>
                <description>Ischemic Stroke</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bleeding</sub_title>
                <description>Gastrointestinal bleeding</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Andre Rodrigues Duraes</name_or_title>
      <organization>Hospital Ana Nery</organization>
      <phone>+557191888399</phone>
      <email>andreduraes@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

